Atara Biotherapeutics

Pascal Touchon, President and CEO 

Oct. 12 | 4:30pm | UBC Ballroom 

San Franciso, CA 


In-person Presentation 

Atara Biotherapeutics is a pioneer in T cell immunotherapy, leveraging its novel allogeneic EBV T cell platform to develop transformative therapies for patients with serious diseases. With our lead program in Phase III clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs or TCRs. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) for EBV+ PTLD; ATA188, a T cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and next-generation CAR T immunotherapies for both solid tumors and hematologic malignancies. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions